Business Context and Reporting Period
This Form 8-K Current Report was filed by Prothena Corporation plc on July 3, 2019, covering events occurring on July 1, 2019. The registrant is an Ireland-based company with its principal executive offices in Dublin, and its ordinary shares trade on the Nasdaq Global Select Market under the symbol PRTA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation matters rather than financial performance.
Material Changes
The primary material change reported is the appointment of Paula K. Cobb as a director of the Company, effective July 1, 2019. No financial material changes were disclosed in this document.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the details of the new director's appointment and compensation package. There is no forward-looking guidance, risk disclosure, or discussion of contingencies in this specific filing. The compensation arrangements for Ms. Cobb include:
- Initial Grant: An option to acquire 35,000 ordinary shares under the 2018 Long Term Incentive Plan. The exercise price is based on the last reported sale price on July 2, 2019. Vesting occurs in equal annual installments over three years, contingent on continuous service.
- Annual Cash Retainer: $60,000 paid in quarterly installments.
- Annual Equity Grant: An annual option to acquire 17,500 ordinary shares. The exercise price is set on the first business day following each annual general meeting. These options vest in full on the earlier of the first anniversary of the grant date or the day prior to the next annual general meeting.
Key Facts for Investor Verification
- Paula K. Cobb was appointed to the Board of Directors effective July 1, 2019.
- Ms. Cobb received an initial stock option grant of 35,000 shares with a three-year vesting schedule.
- Ms. Cobb is eligible for an annual cash retainer of $60,000 and recurring annual stock option grants of 17,500 shares.
- The filing does not contain financial results or operational updates for the period.